Anacetrapib is a CETP inhibitor which was being developed to treat elevated cholesterol levels in an effort to prevent cardiovascular disease. In 2017 its development was abandoned by Merck.
{{chembox | Verifiedfields = changed | verifiedrevid = 444391072 | ImageFile = Anacetrapib.svg | ImageClass = skin-invert-image | ImageSize = 200px | PIN = (4S,5R)-5-[3,5-Bis(trifluoromethyl)phenyl]-3-{[4′-fluoro-2′-methoxy-5′-(propan-2-yl)-4-(trifluoromethyl)[1,1′-biphenyl]-2-yl]methyl}-4-methyl-1,3-oxazolidin-2-one | OtherNames = MK-0859 |Section1= |Section2= |Section3= }} Anacetrapib is a CETP inhibitor which was being developed to treat elevated cholesterol levels in an effort to prevent cardiovascular disease. In 2017 its development was abandoned by Merck.
==Evidence== In 2017 REVEAL trial anacetrapib was shown to decrease the risk of repeat heart attacks in high-risk patients with previous acute coronary events.
Discovered by embedding cosine similarity (sentence-transformers MiniLM, 384-dim).